Imricor Medical Systems (ASX:IMR) reported a total revenue of $132,000 for the March quarter, with its consumables revenue of $104,000 up 385% year-over-year, according to a Wednesday Australian bourse filing.
The firm reported net cash inflows from financing activities of $43 million in the March quarter, comprising net proceeds from the completion of the placement. Meanwhile, its net cash outflows from operating activities came in at $4.6 million.
It also established Imricor BV, a wholly-owned subsidiary in the Netherlands, during the quarter. It hired the first capital sales managers in the US in preparation for a US commercial launch.
On April 10, the first-in-man ventricular ablation guided by real-time interventional cardiac magnetic resonance was performed at the Amsterdam University Medical Centre.
Its shares rose 5% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.